Table 2.
Treatments before blood collection and pathological response to neoadjuvant therapy.
| cStage | Neoadjuvant Therapy CT (Course) + RT (Gy) |
Pathological Response to Neoadjuvant Therapy | cStage | First Line Treatment CT (Course) + RT (Gy) |
|---|---|---|---|---|
| II | CF (1) | 0 | IV | S-1 * (3) |
| CF (2) + RT (40) | 1a | CF (12) | ||
| CF (2) | 1b | CF (5) + RT (60) | ||
| CF (1) | 1a | CF (1) + RT (40) | ||
| CF (1) | 0 | CF (1) + RT (40) | ||
| CF (2) | 0 | CF (5) + RT (60) | ||
| CF (1) | 1a | CF (4) + RT (57) | ||
| CF (2) | 1a | CF (6) | ||
| CF (2) | 2 | CF (2) + RT (60) | ||
| CF (1) + RT (40) | 3 | CF (1) + RT (42) | ||
| CF (2) | 3 | CF (1) + RT (60) | ||
| CF (2) | 2 | CF (1) + RT (39) | ||
| III | CF (1) + RT (40) | 1a | CF (8) | |
| CF (1) + RT (40) | 2 | S-1 ** (8) | ||
| CF (1) + RT (40) | 1b | CF (2) + RT (60) | ||
| CF (1) + RT (40) | 1a | CF (7) + RT (30) | ||
| CF (2) | 1b | |||
| CF (1) + RT (40) | 2 | RT; radiation therapy | ||
| CF (1) + RT (40) | 1b | CF: 5-fluorouracil 700~800 mg/m2 on days 1 to 5, cisplatin 70~80 mg/m2 on day 1, every 3–4 weeks | ||
| CF (2) | 1a | |||
| CF (1) + RT (40) | 1b | |||
| CF (1) | unevaluable | DCF: 5-fluorouracil 750 mg/m2 on days 1 to 5, cisplatin 70 mg/m2 on day 1, docetaxel 70 mg/m2 on day 1, every 3 weeks | ||
| CF (1) + RT (40) | 2 | |||
| CF (1) | 1a | |||
| CF (1) + RT (40) | 1b | |||
| CF (2) | unevaluable | S-1 *: 100 mg/day, orally on days 1 to 14, every 3 weeks | ||
| CF (2) | 1a | |||
| CF (2) + RT (40) | 2 | S-1 **: 100 mg/day, orally on days 1 to 28, every 6 weeks | ||
| DCF (2) | 2 | |||
| DadsCF (3) | 1a | |||
* and ** show the difference in S-1 therapy regimens in two different patients. Pathological response to neoadjuvant therapy was determined using surgical specimens according to the Japanese Classification of Esophageal Cancer, 11th Edition.